NCT04556617View on ClinicalTrials.gov

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

PLX2853 20 mg

PLX2853 tablets

DRUG

Olaparib

Olaparib tablets

DRUG

Abiraterone acetate

Abiraterone acetate tablets

DRUG

Prednisone

Prednisone (or equivalent) tablets

DRUG

PLX2853 40 mg

PLX2853 tablets

DRUG

PLX2853 80 mg

PLX2853 tablets

Trial Locations (8)

10032

Columbia University Medical Center, New York

22031

Virginia Cancer Specialist, Fairfax

29572

Carolina Urologic Research Center, Myrtle Beach

37203

Tennessee Oncology/ Sarah Cannon, Nashville

48201

Karmanos Cancer Institute, Detroit

53792

University of Wisconsin, Madison

60637

University of Chicago, Chicago

W1G 6AD

Sarah Cannon Research Institute, London

Sponsors

Lead Sponsor

Opna Bio LLC
All Listed Sponsors
lead

Opna Bio LLC

INDUSTRY

NCT04556617 - PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter